Differences Between Alpha-Fetoprotein (AFP) and Prothrombine Induced by Vitamin K Absence or Antagonist II (PIVKA-II) Values as Early Detection Method for Hepatocellular Carcinoma (HCC) and Cirrhosis by Nugraha, Bayu Eka et al.
Volume 19, Number 3, December 2018 153
ORIGINAL ARTICLE
Differences Between Alpha-Fetoprotein (AFP) and 
Prothrombine Induced by Vitamin K Absence or 
antagonist II (PIVKA-II) Values as Early Detection Method 
for Hepatocellular Carcinoma (HCC) and Cirrhosis
Bayu Eka Nugraha*, Nugraha Setiawan*, Hani Susianti**, Bogi Pratomo***
*Department of Internal Medicine, Faculty of Medicine,  
Brawijaya University/Dr. Saiful Anwar Hospital, Malang 
**Department of Clinical Pathology, Faculty of Medicine,  
Brawijaya University/Dr. Saiful Anwar Hospital, Malang 
***Division of Gastroentero-hepatology, Department of Internal Medicine, Faculty of Medicine  
Brawijaya University/Dr. Saiful Anwar Hospital, Malang
Corresponding author: 
Bogi Pratomo. Division of Gastroentero-hepatology, Department of Internal Medicine, Dr. Saiful Anwar Hospital. 
Jl. Jaksa Agung Suprapto No. 2 Malang Indonesia. Phone/facsimile: +62-341-348265. E-mail: bogi.pratomo@
yahoo.com
ABSTRACT
Background: Hepatocellular carcinoma is a common cancer worldwide and has a high mortality. Biomarkers 
could theoretically help to detect the disease at an earlier stage before symptoms occur and improve the treatment 
outcomes. The first biomarker found was alpha-fetoprotein/AFP (not very accurate and 30-40% of HCC may 
be missed). Prothrombin induced by vitamin K absence or antagonist II (PIVKA-II) can be used as an early 
detection method to diagnose hepatocellular carcinoma (HCC). 
Method: A cross sectional study on in-patients or out-patients at Dr. Saiful Anwar Malang Hospital from 
July 2016 to October 2016. 
Results: The p value (p > 0.05) obtained using Kolmogorov-Smirnov was 0.166 for diagnosis of HCC and 
0.147 for the diagnosis of hepatic cirrhosis. The p value (p > 0.05) obtained using Shapiro-Wilk was 0.103 for 
diagnosis of HCC and 0.087 for the diagnosis of cirrhosis. Comparative test using the LSD method showed 
PIVKA-II serum levels in HCC as compared to hepatic cirrhosis as significant with a p-value less than 0.05 (p 
< 0.05), that is 0.025. However comparative test using the Tukey HSD method showed that the results obtained 
were not significant. According to the PIVKA-II cut off value, the sensitivity and specificity to detect cirrhosis 
and HCC was as large as 100%. According to the AFP cut off value, the sensitivity to detect cirrhosis and HCC 
was 93.3% and the specificity was 76.92%. 
Conclusion: Both PIVKA-II and AFP can be used to detect cirrhosis and HCC. However PIVKA-II exhibited 
better sensitivity and specificity in the detection of cirrhosis and HCC. 
Keywords: Hepatocellular carcinoma, cirrhosis, alpha-fetoprotein (AFP), prothrombin induced by vitamin 
K absence or antagonist II (PIVKA-II)
ABSTRAK
Latar belakang: Karsinoma sel hati (KSH) merupakan kanker dengan prevalensi yang tinggi di seluruh dunia 
dengan tingkat mortalitas tinggi. Secara teori, biomarker dapat digunakan untuk mendeteksi KSH pada fase 
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awal sebelum terjadi gejala sehingga dapat memberikan prognosis terapi yang lebih baik. Biomarker pertama 
yang ditemukan adalah alpha-fetoprotein/AFP (dengan tingkat akurasi yang lebih rendah, sekitar 30-40% KSH 
dapat terlewatkan). Biomarker prothrombin induced by vitamin K absence or antagonist II (PIVKA-II) dapat 
digunakan sebagai metode deteksi awal untuk mendiagnosis KSH.
Metode: Studi cross sectional pada pasien rawat inap dan rawat jalan di RSU Dr. Saiful Anwar Malang 
mulai bulan Juli 2016 hingga Oktober 2016.
Hasil: Nilai p (p > 0.05) sebesar 0.166 didapatkan dari pengujian Kolmogorov Smirnov untuk diagnosis KSH 
dan 0.147 untuk diagnosis sirosis. Nilai p value (p > 0.05) menggunakan uji Saphiro-Wilk didapatkan sebesar 
0.103 untuk diagnosis KSH dan 0.087 untuk diagnosis sirosis. Pengujian perbandingan menggunakan metode 
LSD menunjukkan level serum PIVKA II pada KSH memiliki perbedaan yang signifikan dibandingkan dengan 
sirosis nilai p < 0.05 yakni sebesar 0.025. Namun uji perbandingan menggunakan Tukey HSD menunjukkan 
bahwa hasil yang didapatkan tidak signifikan. Terkait nilai ambang batas PIVKA II, didapatkan sensitivitas 
dan spesifisitas dalam mendeteksi SH dan KSH hingga 100%. Sedangkan AFP didapatkan sensitivitas sebesar 
93.3% dan spesifisitas sebesar 76.92% dalam mendeteksi sirosis dan KSH
Simpulan: PIVKA-II maupun AFP dapat digunakan untuk mendeteksi sirosis dan KSH. Namun PIVKA II 
memberikan sensitivitas dan spesifisitas yang lebih baik dalam mendeteksi sirosis dan KSH.
Kata kunci: karsinoma sel hati, sirosis hepatis, alpha-fetoprotein (AFP), prothrombin induced by vitamin K 
absence or antagonist II (PIVKA II)
INTRODUCTION
Hepatocellular carcinoma is recently becoming 
worldwide health problem with increasing incidence 
in the last 5 years. According to WHO report in 
2008, HCC caused 600,000 deaths each year in 2004. 
Hepatocellular carcinoma is the 5th most prevalent 
cancer in the world, with 500,000 new cases each 
year. It is the 3rd cause of cancer related death after 
lung and gastric cancer. The incidence of HCC has 
specific geographical distribution, in which it is more 
commonly found in Asia, West Pacific, and South-
East Africa and it is more rarely found in region of 
America, Europe, and Oceania.1,2 Hepatocellular 
carcinoma is the 8th most prevalent cancer in Indonesia, 
especially in Dharmais Cancer Hospital, from 2010 
until 2013. New cases and cancer related death of 
HCC are continuously increasing.3 The burden of the 
disease certainly gives great impact on public health, 
productivity, life expectancy, social, and economic 
aspects of society.4 Patient often visit the doctor in 
the late course of disease because early detection of 
hepatocellular carcinoma is still problematic.
Biomarkers could theoretically help to detect the 
disease at an earlier stage before symptoms occur and 
improve the treatment outcomes. The first biomarker 
found was alpha-fetoprotein (AFP) and it is currently 
used as part of the HCC surveillance recommended 
in many countries. However AFP is not very accurate 
and 30-40% of HCCs may be missed.5 Although serum 
alpha-fetoprotein (AFP) is often elevated in patients 
with HCC, its sensitivity and speci ficity were estimated 
at 41% to 65% and 80% to 94%, respectively, in one 
study.6 It is generally accepted that serum levels greater 
than 500 μ/L in high-risk patients are diagnostic for 
HCC. However, negative values do not rule out HCC. 
AFP also may be elevated in patients with chronic 
liver disease in the absence of cancer (especially with 
inflammation), in pregnancy, tumors of gonadal origin, 
and a variety of other malignancies. Because of the 
limitations of serum AFP measurements, several other 
serum markers of HCC used alone or in combination 
with AFP have been evaluated.7
Des-gamma-carboxy-prothrombin (DCP), which is 
also known as protein induced by vitamin K absence 
or antagonist II (PIVKA-II), is the form of abnormal 
prothrombin. In normal liver function, prothrombin 
precursor undergoes post translation carboxylation 
(adding of carboxylic acid group) by the enzyme of 
gamma glutamyl carboxylase before it is finally released 
into peripheral circulation. Carboxylase depends on 
vitamin K. This enzyme is not found in the case of HCC, 
which causes abnormal prothrombin to be secreted in 
circulation.4 The aims of this study was investigating 
the role DCP/PIVKA-II as a marker in early detection 
method of diagnosing HCC. Early detection of HCC 
will bring the treatment to be given earlier which may 
give a better prognosis for the patient.
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METHOD
This was an analytical cross-sectional study which 
was carried on inpatient and outpatient clinic of Dr. 
Saiful Anwar Hospital, Malang. The study has been 
reviewed and accepted by the Ethical Committee Board 
of  Dr. Saiful Anwar Hospital, Malang. 
All HCC and hepatic cirrhosis patients, that came 
to outpatient clinic or had been hospitalized, from July 
2016 until October 2016 in Dr. Saiful Anwar Hospital, 
Malang, were recruited to the study. The eligible 
subjects from study period were 28 patients.
Inclusion criteria for sample selection were male/
female with established diagnosis of hepatocellular 
carcinoma or hepatic cirrhosis. The diagnosis 
was confirmed from history taking, physical 
examination, and additional examination such as 
imaging examination, biological marker examination, 
etc. Exclusion criteria included male/female with 
hepatocellular carcinoma or hepatic cirrhosis was got 
treatment for his/her disease 
Analysis of PIVKA and AFP was done parametrically 
using ANOVA. Assumption of normality and 
assumption of homogeneity of variance are the two 
assumptions that became the basis of ANOVA. Test 
for normality assumption was performed using Saphiro 
Wilk test. Normality of data was fulfilled if p-value 
of the test was > 0.05. If the assumption of normality 
was not achieved, in which the p-value was < 0.05, 
the analysis of hypothesis could be performed non-
parametrically. The research analyzed the comparison 
between AFP and PIVKA measurement in HCC.
RESULTS
Results showed different values of sensitivity and 
specificity of AFP and PIVKA in the detection of 
hepatic cirrhosis and hepatocellular carcinoma. AFP 
had sensitivity about 93.33% and specificity about 
76.92% in the detection of hepatic cirrhosis and 
hepatocellular carcinoma. According to the Konsensus 
Nasional Penatalaksanaan Karsinoma Sel Hati, AFP 
has diagnostic value with cut-off point of >200 ng/mL 
and the cut-off point for PIVKA II is > 40 mAU/mL. 
Cut off value of AFP is described in Table 1. Table 2 
describe the cut off value of PIVKA-II in detecting 
hepatic cirrhosis and hepatocellular carcinoma, with 
100% sensitivity and specificity. 
DISCUSSION
Hepatocellular carcinoma (HCC) is the most 
common primary malignancy of the liver.8 The global 
burden of this cancer in 2012 was an all-time high 
with 14 million cases and it is predicted to grow to 22 
million cases over the next two decades.9 Liver cancers 
have the seventh highest age-adjusted incidence rate 
in the world, with 0.8 million cases diagnosed for the 
year of 2012.10 Its most common etiological factor in 
the world is hepatitis B virus (HBV) infection. The 
development of cirrhosis is also associated with high 
risk for developing HCC, with the most common 
risk factors including alcohol, viral hepatitis such as 
hepatitis C virus (HCV) infection, and non-alcoholic 
fatty liver disease (NAFLD). Due to its high prevalence, 
HCC carries a significant economic burden on society, 
especially in East Asian countries where HBV infection 
is endemic. HCC is the third most common cause of 
cancer-related death in the world and the seventh most 
common cause in the United State (US). Surveillance 
programs have also been implemented to screen for 
HCC in high-risk individuals, which is more cost 
effective than the treatment of HCC.9,10
The initial approach in the management of HCC 
is to determine if either surgical resection or liver 
transplantation is feasible. Since the majority of HCC 
cases develop in cirrhotic patients, surgical interventions 
Table 2. Contigency table for PIVKA-II in patient with 
hepatocellular carcinoma (HCC) and hepatic cirrhosis (HC)
Diagnosis
Prothrombin Induced by Vitamin K 
Absence or antagonist II (PIVKA-II)
H e p a t o c e l l u l a r 
carcinoma (HCC)
Hepatic cirrhosis 
(HC)
Hepatocellular 
carcinoma (HCC)
17 0
Hepatic cirrhosis 
(HC)
0 11
Total 17 11
Sensitivity:  17/17 x 100% = 100%; specificity: 11/11 x 100% = 100%; positive 
predictive value (PPV): 17/17 x 100% = 100%; negative predictive value (NPV) 
= 11/11 x 100% = 100%; Accuracy = 100%; positive likelihood ratio (LR+)= ~ 
; negative Likelihood ratio (LR-)= 0
Table 1. Contigency table for alpha-fetoprotein (AFP) in patient 
with hepatocellular carcinoma (HCC) and hepatic cirrhosis (HC)
Diagnosis
Alpha-fetoprotein (AFP)
H e p a t o c e l l u l a r 
carcinoma (HCC)
Hepatic cirrhosis 
(HC)
Hepatocellular 
carcinoma (HCC)
14 3
Hepatic cirrhosis 
(CC)
1 10
Total 15 13
Sensitivity:  14/15 x 100% = 93.33%; specificity: 10/13 x 100% = 76.92%; 
positive predictive value (PPV) = 14/17 x 100% = 82.35%; negative predictive 
value (NPV) = 10/11 x 100% = 90.91%; Accuracy = 85.71%; positive likelihood 
ratio (LR+)= 4.04; negative likelihood ratio (LR-)= 0.09
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can become challenging and the treatment has been 
directed toward liver transplantation. Certainly, 
prevention of cancer development seems to be the 
appropriate strategy to solve the problem regarding 
shortage of donor organs. Hence, understanding the 
epidemiology, etiology, and pathogenesis of this 
economically burdening cancer is of prime significance 
for hepatologist and oncologist.11
Hepatocellular carcinoma is more common among 
males with male and female ratio worldwide is 2.4.12 
The most common age at presentation is usually 
between 30 and 50 years.13 HCC is predominant in 
Asian countries including China, Mongolia, Southeast 
Asia, Sub-Saharan, Western and Eastern Africa. The 
prevalence of HCC in developed countries of the world 
is lower, except Japan, Italy, and France.11
In the previous guideline, groups were specified 
for which surveillance was likely to be cost-effective 
because the hepatocellular carcinoma (HCC) incidence 
was high enough. New data on defining HCC risk 
have emerged for hepatitis B virus, hepatitis C virus, 
and autoimmune hepatitis. Surveillance is deemed 
cost-effective if the expected HCC risk exceeds 1.5% 
per year in patients with hepatitis C and 0.2% per 
year in patients with hepatitis B. Analysis of recent 
studies show that alpha-fetoprotein determination 
lacks adequate sensitivity and specificity for effective 
surveillance (and for diagnosis).14
Alpha-fetoprotein is one of glycoprotein, synthesized 
by hepatocyte and saccus vitelinus. It is usually found 
in the serum of fetus. In 2 weeks after delivery, AFP 
in serum is mostly undetectable. In normal person, 
AFP is only found in relatively small amount (< 
25 ng/mL). When the hepatocyte changed to be a 
malignant cell, it will produce AFP. The concentration 
of AFP in the serum will increase as a tumor marker, 
although it isn’t always found in all hepatocellular 
carcinoma. Concentration of AFP increase in 50-90% 
of hepatocellular carcinoma patient. Increase of AFP 
> 200 ng/mL in patient with hepatic cirrhosis which 
is accompanied by mass at hepatic region, increase 
the possibility of hepatocellular carcinoma. Alkaline 
phosphatase can be used as screening and diagnostic 
measurement, and also monitoring after treatment.1
The absence of effective treatment in the late stage 
of HCC favors the early detection and also screening 
procedure especially in high risk population. Recently, 
early diagnosis of HCC becomes an important 
strategy in the management of HCC. Not all imaging 
technique can detect liver cancer immediately after 
the development of tumor. In some cases, oncologists 
use alpha-fetoprotein (AFP) as a marker for liver 
cancer beside imaging technique. Des-gamma-carboxy 
prothrombin (DCP), which is also known as protein 
induced by vitamin K absence or antagonist II 
(PIVKA-II), is recently used in the early detection of 
hepatocellular carcinoma, because as a non-functional 
prothrombin, PIVKA-II is produced by liver in the 
condition of vitamin K deficiency as in HCC.15
PIVKA-II is a more sensitive and specific marker 
for early detection of HCC than AFP, because in the 
case of HCC, the abnormal liver tissue produces 
higher concentration of non-functional prothrombin 
precursor which certainly will influence the production 
of PIVKA-II. It was also suggested in some studies 
that PIVKA-II has property to differentiate HCC 
histopathologically and it has a good diagnostic 
validity to evaluate portal vein thrombosis. Those 
properties are useful in differentiating early and late 
stage of HCC. Direct correlation between PIVKA-
II concentration and tumor size, makes this marker 
became new attractive marker for research in early 
diagnosis and survival prediction of HCC. Besides, 
the high sensitivity and specificity of PIVKA-II 
can be beneficial in the screening process of high-
risk population and also early stage diagnosis of 
HCC, therefore patients can still be given curative 
treatment.4,15
This study revealed 100% sensitivity and specificity 
of PIVKA in detecting HCC, compared with only 
93.33% sensitivity and 76.92% specificity of AFP. Our 
results are consistent with those from Marrero et al and 
Durazo et al, in which they found that PIVKA-II was 
more sensitive than AFP in differentiating HCC from 
patient with hepatic cirrhosis or chronic hepatitis, with 
sensitivity of 89% and specificity of 87%.16,17
Clinical significance of tumor markers in HCC 
diagnosis remains controversial. The potential roles 
played by tumor markers, tend to be underrated in 
Western reports, although it is considered of greater 
value in Eastern setting. Recently, a combination of 
AFP and PIVKA-II levels has been recommended for 
diagnosing HCC malignancy in Japan.18 Limitations of 
the study include small sample size of and long term 
follow up of the participants was not taken. In Future 
a study can be done with larger sample size.
CONCLUSION
PIVKA and AFP examinations both can be applied 
in detecting hepatocellular carcinoma and hepatic 
cirrhosis. PIVKA has some advantages, compared to 
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AFP, in detecting HCC and hepatic cirrhosis. Cut off 
value of PIVKA gave 100% sensitivity and specificity 
in detecting hepatic cirrhosis and HCC, while cut off 
value of AFP gave 93.3% sensitivity and 76.92% 
specificity.
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